• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

男性下尿路症状患者应用α受体阻滞剂治疗后自主神经系统活动的变化。

Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms.

机构信息

Department of Urology, Ajou University College of Medicine, Suwon, Korea.

Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Investig Clin Urol. 2018 Jan;59(1):49-54. doi: 10.4111/icu.2018.59.1.49. Epub 2017 Dec 15.

DOI:10.4111/icu.2018.59.1.49
PMID:29333515
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5754583/
Abstract

PURPOSE

To determine changes in autonomic nervous system activity after treatment in men with lower urinary tract symptoms (LUTS), we evaluated changes in patients' symptoms, uroflowmetry, and heart rate variability (HRV) after treatment with alpha-blockers for 12 weeks.

MATERIALS AND METHODS

Ninety-five men who had LUTS (International Prostate Symptom Score [IPSS] ≥8) were included in this study. We divided them into two groups on the basis of a low frequency/high frequency (LF/HF) ratio of 1.6. After treatment with Xatral XL (Handok Inc., Korea) 10 mg for 3 months, we rechecked their IPSS, uroflowmetry, HRV and compared these with the baseline measurements.

RESULTS

Fifty-four men were assigned to the low LF/HF group (group A: LF/HF ≤1.6) and 41 men to the high LF/HF group (group B: LF/HF >1.6). At baseline and 12 weeks, none of the parameters differed significantly between the groups except for HF, which is one of the parameters of HRV. IPSS, the IPSS-voiding subscore, and the IPSS-storage subscore decreased and maximal uroflow increased significantly after 12 weeks of treatment. Whereas the baseline LF/HF ratio increased from 0.89±0.407 to 1.80±1.804 after treatment in group A, it decreased from 3.93±5.471 to 1.79±1.153 in group B.

CONCLUSIONS

The efficacies of Xatral XL were clear in both groups. We found that the LF/HF ratio in the two groups merged to a value of approximately 1.79 after treatment. We suggest that this could be a clue to the importance of balance in autonomic nervous system activity in men with LUTS.

摘要

目的

通过评估男性下尿路症状(LUTS)患者在接受α受体阻滞剂治疗 12 周后症状、尿流率和心率变异性(HRV)的变化,来确定自主神经系统活动的变化。

材料和方法

本研究共纳入 95 例 LUTS 患者(国际前列腺症状评分[IPSS]≥8)。我们根据低频/高频(LF/HF)比值将他们分为两组,比值为 1.6。在服用 Handok Inc.(韩国)生产的 Xatral XL(10mg)治疗 3 个月后,我们重新检查了他们的 IPSS、尿流率,并与基线测量值进行了比较。

结果

54 例患者被分到 LF/HF 比值较低的组(A 组:LF/HF≤1.6),41 例患者分到 LF/HF 比值较高的组(B 组:LF/HF>1.6)。在基线和 12 周时,除 HRV 的一个参数 HF 外,两组之间的所有参数均无显著差异。IPSS、IPSS 排尿分量表和 IPSS 存储分量表在治疗 12 周后均显著下降,最大尿流率显著增加。而在 A 组,治疗后 LF/HF 比值从 0.89±0.407 增加到 1.80±1.804,B 组则从 3.93±5.471 减少到 1.79±1.153。

结论

Xatral XL 在两组中的疗效均明显。我们发现两组的 LF/HF 比值在治疗后均合并为约 1.79。我们认为这可能是男性 LUTS 患者自主神经系统活动平衡重要性的线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5a/5754583/09c9e15246cc/icu-59-49-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5a/5754583/2b38bb19d814/icu-59-49-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5a/5754583/09c9e15246cc/icu-59-49-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5a/5754583/2b38bb19d814/icu-59-49-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f5a/5754583/09c9e15246cc/icu-59-49-g002.jpg

相似文献

1
Changes in autonomic nervous system activity after treatment with alpha-blocker in men with lower urinary tract symptoms.男性下尿路症状患者应用α受体阻滞剂治疗后自主神经系统活动的变化。
Investig Clin Urol. 2018 Jan;59(1):49-54. doi: 10.4111/icu.2018.59.1.49. Epub 2017 Dec 15.
2
Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).索利那新联合坦索罗辛 OCAS 治疗排尿和储尿期下尿路症状男性患者的疗效和安全性:一项 2 期剂量探索研究(SATURN)的结果。
Eur Urol. 2013 Sep;64(3):398-407. doi: 10.1016/j.eururo.2013.03.031. Epub 2013 Mar 19.
3
Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.索利那新与坦索罗辛口服控释系统单片复方制剂治疗男性储尿和排尿下尿路症状的长期安全性和疗效:NEPTUNE 研究和 NEPTUNE II 开放性扩展研究结果。
Eur Urol. 2015 Feb;67(2):262-70. doi: 10.1016/j.eururo.2014.07.013. Epub 2014 Jul 25.
4
Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).他达拉非改善提示良性前列腺增生的下尿路症状患者的症状、勃起功能及生活质量(KYU-PRO研究)。
Low Urin Tract Symptoms. 2018 Jan;10(1):76-83. doi: 10.1111/luts.12143. Epub 2016 Nov 5.
5
Characteristics of autonomic nervous system activity in men with lower urinary tract symptoms (LUTS): analysis of heart rate variability in men with LUTS.男性下尿路症状 (LUTS) 患者自主神经活动特征:LUTS 男性心率变异性分析。
Urology. 2010 Jan;75(1):138-42. doi: 10.1016/j.urology.2009.08.018. Epub 2009 Oct 24.
6
Tailoring Medication for Lower Urinary Tract Symptoms in Men Based on International Prostate Symptom Score Voiding to Storage Ratio.基于国际前列腺症状评分排尿与储尿比值为男性下尿路症状量身定制药物治疗
Urology. 2018 Oct;120:30-35. doi: 10.1016/j.urology.2018.06.040. Epub 2018 Jul 7.
7
Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.有症状的良性前列腺增生男性下尿路症状的严重程度反映了膀胱储尿功能障碍和膀胱出口梗阻的不同构成。
Int J Clin Pract. 2014 Jun;68(6):743-8. doi: 10.1111/ijcp.12364. Epub 2014 Jan 29.
8
Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.加压素联合治疗在接受 α 受体阻滞剂治疗下尿路症状的男性患者中难治性夜间尿频。
J Urol. 2013 Jul;190(1):180-6. doi: 10.1016/j.juro.2013.01.057. Epub 2013 Jan 25.
9
Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.一项前瞻性、随机、多中心、双盲、安慰剂对照研究:对于伴有逼尿肌过度活动症的下尿路症状的良性前列腺增生症患者,初始联合应用抗胆碱能药物和 α 受体阻滞剂治疗。
Prostate Cancer Prostatic Dis. 2011 Dec;14(4):320-5. doi: 10.1038/pcan.2011.22. Epub 2011 Jul 26.
10
The correlation between the treatment efficacy and the sympathetic activity in men with lower urinary tract symptoms.男性下尿路症状与交感活性之间的治疗效果相关性。
Int Neurourol J. 2014 Sep;18(3):145-9. doi: 10.5213/inj.2014.18.3.145. Epub 2014 Sep 24.

引用本文的文献

1
Changes in Autonomic Nervous System Activity in Children With Spina Bifida: A Case-Control Study.脊柱裂患儿自主神经系统活动的变化:一项病例对照研究。
Int Neurourol J. 2023 Sep;27(3):192-199. doi: 10.5213/inj.2346080.040. Epub 2023 Sep 30.
2
Evaluation of psychological stress, cortisol awakening response, and heart rate variability in patients with chronic prostatitis/chronic pelvic pain syndrome complicated by lower urinary tract symptoms and erectile dysfunction.慢性前列腺炎/慢性盆腔疼痛综合征合并下尿路症状和勃起功能障碍患者的心理压力、皮质醇觉醒反应及心率变异性评估
Front Psychol. 2022 Nov 4;13:903250. doi: 10.3389/fpsyg.2022.903250. eCollection 2022.

本文引用的文献

1
Korean clinical practice guideline for benign prostatic hyperplasia.韩国良性前列腺增生临床实践指南。
Investig Clin Urol. 2016 Jan;57(1):30-44. doi: 10.4111/icu.2016.57.1.30. Epub 2016 Jan 11.
2
Alpha-Blocker Treatment Response in Men With Lower Urinary Tract Symptoms Based on Sympathetic Activity: Prospective, Multicenter, Open-Labeled, Observational Study.基于交感神经活动的下尿路症状男性患者α受体阻滞剂治疗反应:前瞻性、多中心、开放标签、观察性研究。
Int Neurourol J. 2015 Jun;19(2):107-12. doi: 10.5213/inj.2015.19.2.107. Epub 2015 Jun 29.
3
Neural mechanisms underlying lower urinary tract dysfunction.
下尿路功能障碍的神经机制
Korean J Urol. 2014 Feb;55(2):81-90. doi: 10.4111/kju.2014.55.2.81. Epub 2014 Feb 14.
4
The difference of lower urinary tract symptoms between sympathetic hyperactive and hypoactive men.交感神经兴奋型与抑制型男性下尿路症状的差异。
Int Neurourol J. 2013 Mar;17(1):30-3. doi: 10.5213/inj.2013.17.1.30. Epub 2013 Mar 31.
5
Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men.神经调节因子对老年男性下尿路症状/良性前列腺增生和勃起功能障碍发展的影响。
Urol Clin North Am. 2012 Feb;39(1):77-88. doi: 10.1016/j.ucl.2011.09.005. Epub 2011 Oct 13.
6
Evidence for autonomic nervous system dysfunction in females with idiopathic overactive bladder syndrome.女性特发性过度膀胱综合征中自主神经系统功能障碍的证据。
Neurourol Urodyn. 2011 Nov;30(8):1467-72. doi: 10.1002/nau.21154. Epub 2011 Jun 29.
7
Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).治疗良性前列腺增生症(BPH)的新型药物靶点。
Br J Pharmacol. 2011 Jul;163(5):891-907. doi: 10.1111/j.1476-5381.2011.01332.x.
8
Characteristics of autonomic nervous system activity in men with lower urinary tract symptoms (LUTS): analysis of heart rate variability in men with LUTS.男性下尿路症状 (LUTS) 患者自主神经活动特征:LUTS 男性心率变异性分析。
Urology. 2010 Jan;75(1):138-42. doi: 10.1016/j.urology.2009.08.018. Epub 2009 Oct 24.
9
Treatment options for benign prostatic hyperplasia in older men.老年男性良性前列腺增生的治疗选择。
Med Sci Monit. 2008 Jul;14(7):RA94-102.
10
Visual analog scale questionnaire to assess quality of life specific to each symptom of the International Prostate Symptom Score.用于评估国际前列腺症状评分中每种症状特定生活质量的视觉模拟量表问卷。
J Urol. 2006 Aug;176(2):665-71. doi: 10.1016/j.juro.2006.03.031.